AMDL Wins Chinese Military Supply Agreement for Its Domperidone Product for up to $6.6 Million
January 30 2008 - 9:00AM
PR Newswire (US)
TUSTIN, Calif., Jan. 30 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi, and Jilin, China, through its wholly owned
subsidiary Jade Pharmaceutical Inc., (JPI) is an international
biopharma company that, together with JPI, engages in the
development, manufacture and marketing of proprietary
pharmaceutical, health care and diagnostic products. The Company
announced today that JPI's subsidiary, JJB, won a supply contract
for the delivery of Domperidone to the Chinese Military through
HaiHong Pharmaceutical E-Commerce Account Settlement Service Ltd.,
the Chinese agents for the Chinese Military Planned Drugs Online
Focused Purchase Campaign. Frank Zheng, Managing Director of JPI,
stated that "this distribution agreement will position JJB to
become the premier supplier for the Military Strategic Drug
Reserve. It is estimated that Domperidone could realize sales of
approximately $6.6 million in 2008 through this individual
contract. JPI is also promoting other JJB and YYB products through
this supply channel and is confident that additional products from
JJB and YYB will also win bids." Mr. Gary Dreher, CEO of AMDL noted
that "this new distribution channel illustrates JPI's ability to
execute on its 2008 business plan and significantly improves JPI's
ability to grow its sales in 2008 and beyond." About Domperidone:
Domperidone is an important medicine for treating nausea and
vomiting. JPI's generic version of this product is significantly
lower priced than other China pharma competitors. About Jade
Pharmaceutical Inc.: JPI has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiaries, JPI currently manufactures large volume
injection fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures 107 generic, over
the counter and supplemental pharmaceutical products under
certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be
obtained at http://www.amdl.com/. Forward-Looking Statements This
news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct
Line: 949.707.5365 VoiceMail: 714.505.4460 DATASOURCE: AMDL, Inc.
CONTACT: AMDL Investor Relations, Mr. Paul Knopick,
+1-949-707-5365, voicemail, +1-714-505-4460, for AMDL, Inc. Web
site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024